
Inside Bold Care's Bold Bet: How One Startup Sparked India's Sexual Wellness Revolution
"People were desperately looking for solutions, but the market was dominated by unorganised players selling hope, not help," shares Rajat Jadhav, co-founder, Bold Care
Opinions expressed by Entrepreneur contributors are their own.
You're reading Entrepreneur India, an international franchise of Entrepreneur Media.
In 2015, while working on his e-pharmacy startup, Rajat Jadhav stumbled upon a curious pattern. Nearly 40 per cent of orders and queries were for sexual health products despite it being a category no one openly talked about. The products themselves were often sketchy, ranging from Japani oils to vague homoeopathic remedies with little to no clinical backing.
"There was so much demand, but no real trust," Jadhav recalls. "People were desperately looking for solutions, but the market was dominated by unorganised players selling hope, not help."
That single observation would eventually lead to the birth of Bold Care, a brand that not only wanted to sell products but change the narrative around men's health and intimacy in India.
Cracking the silence around male wellness
Sexual wellness has long been India's unspoken frontier. It sits at the intersection of health, masculinity, shame, and misinformation. From awkward chemist visits to late-night TV ads promoting dubious cures, the space was shrouded in embarrassment.
"When we started talking about conditions like erectile dysfunction or premature ejaculation, it wasn't easy," Jadhav admits. "We were breaking years of stigma, and no one wanted to be the first to talk about it."
Launched in July 2020, Bold Care was born during the pandemic, a time when e-commerce boomed, and private wellness quietly became a national priority. But Jadhav and his team weren't just another D2C startup chasing clicks. They wanted to rebuild the ecosystem.
"We don't just launch a pill or cream because the market is hot," Jadhav says. "Each product is designed with multiple benefits and regular use in mind, because that's what builds long-term confidence."
So Bold Care made a bold move: embrace the awkward. Instead of tiptoeing, the brand leaned into the discomfort, adding humour, relatability, and science to the conversation. Whether through social media posts, clever packaging, or customer engagement, the aim was always the same: normalise it.
Going mainstream with a star cofounder
In 2023, Bold Care announced actor and entrepreneur Ranveer Singh as a cofounder. Known for his flamboyance and unapologetic energy, Singh brought both visibility and credibility to the category.
"Ranveer didn't just lend his face, he lent his brain," says Jadhav. "He's deeply involved in branding, storytelling, even product insights. His lived experience as an artist and entrepreneur is invaluable."
The collaboration helped position Bold Care not just as a product, but as a cultural movement, destigmatising male health with humour, empathy, and pride.
Blooming bloom
While Bold Care gained momentum among male consumers, there was growing demand from women either directly or as caregivers, partners, and buyers.
"We started getting countless inquiries from women, asking: What about us?" Jadhav shares.
The answer came in the form of Bloom by Bold Care, a dedicated vertical focused on female sexual health, intimate hygiene, and menopause support. Led by Parinita Hendre and a team of women entrepreneurs, Bloom is disrupting a space just as underserved.
"There's no one-size-fits-all in women's health," Jadhav explains. "From hormonal shifts to age-based nutrition, the needs evolve. Bloom was built to evolve with them."
In just five months, Bloom has already served over 1 lakh customers, and Jadhav predicts it will reach Bold Care's current scale in half the time.
Despite being available on Amazon, Flipkart, Blinkit, Zepto, and Instamart, Bold Care's own website remains the strongest growth engine.
"Direct-to-consumer gives us insights no platform can. We know what our users want, what language they use, what worries them," Jadhav says.
That user insight has shaped everything—from product innovation to customer support scripts. Bold Care also invests heavily in its expert advisory team, helping users make informed, comfortable choices without shame.
The company has also embraced quick commerce, capitalising on impulse buys and the privacy of at-home delivery. "You no longer need to walk into a store or wait three days. With Blinkit and Zepto, your wellness is 10 minutes away," he quips.
Fact Sheet
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Hims & Hers (HIMS) Jumps 6.76% Anew as Investors Cheer Weight Loss Drug Fight
Hims & Hers Health, Inc. (NYSE:HIMS) is one of the . Hims & Hers extended its rally for the second day on Friday, adding 6.76 percent to close at $49.41 apiece after its chief executive's reaffirmation that the company will continue to offer cheaper compounded versions of GLP-1 weight-loss drugs, following its terminated partnership with Novo Nordisk. According to Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum, he was upset that Novo was feeling the pressure and was not comfortable. A nurse in a telehealth platform talking with a patient on video call for consultation. 'But ultimately, I think us holding strong to fighting on behalf of customers is just who we are. There's just no way in hell we're going to cave on that, no matter who the pharma company is or what the partnership looks like,' he noted. Novo Nordisk terminated its partnership with Hims & Hers Health, Inc. (NYSE:HIMS), alleging the latter of failing to adhere to the law, which prohibits mass sales of compounded drugs under the false guise of 'personalization.' Novo Nordisk also claimed that Hims & Hers Health, Inc. (NYSE:HIMS) was disseminating deceptive marketing that put patient safety at risk. While we acknowledge the potential of HIMS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.


CBS News
an hour ago
- CBS News
Allegheny Health Network and Cigna Healthcare announce 3-year contract agreement
On Friday, Allegheny Health Network and Cigna Healthcare announced a new, three-year contract agreement that will ensure those on Cigna insurance will continue to have access to AHN facilities. "This contract is fantastic news for the more than 20,000 Cigna members in this region who rely on AHN for their care," said AHN President Mark Sevco. "It ensures continued, in-network access to AHN's expert clinicians, and to the exceptional-quality, high-value care that their members and our patients expect and deserve." Beneficiaries will continue to have in-network access to AHN's clinical programs, 14 hospitals, and the doctors and specialists employed by AHN. Patients who have appointments in the next week will still be able to keep them, and the new contract goes through June 30, 2028. Those covered by Cigna insurance who may have questions about the new contract can call the Cigna customer service line at 1-800-997-1654.
Yahoo
2 hours ago
- Yahoo
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential
The healthcare sector offers an abundance of high-growth investment opportunities. Companies leveraging artificial intelligence and genomic medicine are delivering innovative therapies with significant potential. Small-cap and under-the-radar stocks with strong growth possibilities merit closer investor attention. 10 stocks we like better than TransMedics Group › There's a strong case that healthcare is the most important sector in the stock market. These companies deliver innovative therapies and medical technologies that are often life-saving. Investors stand to benefit as healthcare leaders and emerging players address the needs of an aging global population and the rising prevalence of chronic diseases. Here are 10 under-the-radar healthcare stocks that could be great buys for your portfolio. Certara (NASDAQ: CERT) is poised to capitalize on the transformation in medicine driven by artificial intelligence (AI), providing bio-simulation software and services that accelerate drug development. The company plays a crucial role in the pharmaceutical industry. Over 90% of all novel drugs approved by the Food and Drug Administration (FDA) since 2014 have leveraged its technology. Its AI-driven solutions enhance research and development (R&D), enabling faster and more precise drug development. Certara deserves a closer look by investors seeking to tap into the AI-driven healthcare transformation. Beam Therapeutics (NASDAQ: BEAM) is a clinical-stage biotech pioneering precision-based gene editing therapies for genetic diseases, including sickle cell disease. Its innovative technology enables precise single-nucleotide DNA changes, potentially offering a safer alternative to traditional CRISPR genetic engineering. Beam has reported early success in gene correction, with its lead candidate, BEAM-101, in phase 1/2 trials for sickle cell disease. While the company still has a lot to prove, its differentiated approach and clinical progress position it for remarkable growth in the long term. Inspire Medical Systems (NYSE: INSP) develops implantable neurostimulation devices for obstructive sleep apnea, offering its FDA-approved Inspire therapy as a noninvasive alternative to CPAP machines. In its first quarter (the period ended March 31), revenue surged 23% year over year to $201 million, driven by growing U.S. adoption and new international approvals. With increasing demand for sleep apnea treatment, Inspire has a significant opportunity to capture market share. Insulet (NASDAQ: PODD) specializes in tubeless insulin pump technology. Its Omnipod system simplifies diabetes management for Type 1 and insulin-dependent Type 2 patients globally, offering convenience and improved outcomes. With a 2025 revenue growth target of 19% to 22%, the company is poised for continued expansion, particularly in underpenetrated international markets. Insulet's strong growth trajectory positions it to reward shareholders further. Krystal Biotech (NASDAQ: KRYS) focuses on rare skin diseases. Its FDA-approved gene therapy, Vyjuvek, for dystrophic epidermolysis bullosa (fragile skin that blisters easily) is expected to approach $400 million in revenue this year, solidifying its position as a best-in-class treatment. Vyjuvek's success validates Krystal's R&D, bolstering confidence in its pipeline and unlocking added market potential. LifeMD (NASDAQ: LFMD) operates a telehealth platform providing specialized virtual care in weight loss, men's health, and dermatology. A partnership with Novo Nordisk to offer Wegovy, a leading GLP-1 treatment, has driven impressive growth, with first-quarter revenue surging 49% year over year for the period ended March 31. LifeMD could expand its growing user base into a comprehensive health management ecosystem to fuel growth and solidify its telehealth leadership. Option Care Health (NASDAQ: OPCH) is the leading U.S. provider of home and alternative-site infusion services, delivering crucial therapies for chronic and acute conditions like cancer, immune deficiencies, and infections. As the healthcare industry shifts toward more personalized and cost-effective care, Option Care Health is in position to capitalize on the strong demand, with its extensive network and high-quality services. Tempus AI (NASDAQ: TEM) harnesses artificial intelligence to advance precision medicine, using its collection of clinical and molecular data from more than 40 million patients to power diagnostics in oncology, cardiology, and beyond. The company projects its revenue to climb by more than 80% this year, to about $1.3 billion. Tempus AI's scalable platform and extensive data ecosystem present substantial opportunities for expansion and impact in personalized healthcare. TransMedics Group (NASDAQ: TMDX) has revolutionized organ transplantation with its Organ Care System (OCS), the only FDA-approved device for heart, lung, and liver transplants that extends organ preservation time. The company's projected revenue growth of 30% this year underscores the strong momentum in a global expansion opportunity. Veeva Systems (NYSE: VEEV) offers cloud-based software that streamlines clinical, regulatory, and commercial processes for life sciences companies. Serving over 1,000 customers, including major pharmaceutical companies and emerging biotechs, Veeva's platform is well positioned to capitalize on the industry's increasing reliance on digital solutions for innovation and compliance. Before you buy stock in TransMedics Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and TransMedics Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Dan Victor has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Beam Therapeutics, Inspire Medical Systems, TransMedics Group, and Veeva Systems. The Motley Fool recommends Insulet, Krystal Biotech, and Novo Nordisk. The Motley Fool has a disclosure policy. 10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential was originally published by The Motley Fool